Ascentage Pharma, IPO

IPO market comeback: How recent major US listings fared
The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...
3FPX, ARM : IPO Rebound In 2025? Here's What's Fueling The Boom,...
The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...
FierceBiotech9h
‘A really rational IPO environment’: What does it takes for a biotech to go public now?
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...
Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
Denta Water and Infra IPO day 3: GMP, subscription status to review. Should you apply as bidding ends today?
According to market observers, shares of the company are available at a premium of ₹151 in the grey market today ...
Trump Partner Builds $1 Billion Stake From India Real Estate IPO
When Donald Trump’s real estate business wanted to break into the Indian market in 2012, it turned to Atul Chordia and his ...
2024 Year In Review: IPO Market Overview
In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...
FierceBiotech14h
Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...